Header Logo

Connection

Michael Jelinek to Ipilimumab

Back to Details
This is a "connection" page, showing publications Michael Jelinek has written about Ipilimumab.
Michael Jelinek
Connection Strength
0.049
Ipilimumab
  1. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.